Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Tumour characteristics and therapeutic results after percutaneous radiofrequency ablation of secondary lung neoplasms
Clinical and Translational Oncology, 06/30/09
Dequanter D et al. - RFA seems to be possible for “non-surgical” patients with various histologic types of secondary lung tumours. Good results in terms of local tumour control validated by contrast-enhanced CT scan were observed during short-term follow-up evaluation.
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?
Annals of Oncology, 11/17/09
Ovarian cancer screening and early detection
Women's Health, 11/04/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/09
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


